US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CLIMB BIO INC

2.12

+0.11005.47%

Volume:407.38K

Turnover:863.78K

Market Cap:143.66M

PE:-3.06

High:2.19

Open:2.02

Low:2.02

Close:2.01

52wk High:8.60

52wk Low:1.05

Shares:67.76M

Float Shares:25.58M

Volume Ratio:1.14

T/O Rate:1.59%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.6934

EPS(LYR):-1.5343

ROE:-22.92%

ROA:-15.83%

PB:0.77

PE(LYR):-1.38

Loading ...

Overview Company News Filings

Climb Bio Inc. Announces Leadership Changes: Brett Kaplan Departs, Aoife Brennan Appointed Interim Principal Financial Officer

Climb Bio Inc. Announces Inducement Equity Award Grant for New Employee Under 2025 Inducement Plan

BRIEF-Climb Bio Reports First Quarter 2025 Financial Results

Climb Bio Q1 EPS $(0.31) Misses $(0.15) Estimate

Climb Bio Inc. Reports Q1 2025 Financial Results with Increased R&D Expenses Amid Strong Cash Position; No Specific Sales or Net Income Data Provided

Press Release: Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Press Release: Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

BRIEF-Climb Bio Files For Offering Of Common Stock Up To $22.4 Million - SEC Filing

Climb Bio Reports Fourth Quarter And Year-End 2024 Financial Results And Provides Business Updates

Climb Bio Q4 2024 GAAP EPS $(0.13) Beats $(0.15) Estimate

Press Release: Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CLYM/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CLYM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLYM\",,,,,undefined,":{"symbol":"CLYM","market":"US","secType":"STK","nameCN":"CLIMB BIO INC","latestPrice":2.12,"timestamp":1758136813994,"preClose":2.01,"halted":0,"volume":407384,"delay":0,"floatShares":25579273,"shares":67764100,"eps":-0.693447,"marketStatus":"Trading","change":0.11,"latestTime":"09-17 15:20:43 EDT","open":2.02,"high":2.185,"low":2.02,"amount":863777.5173519999,"amplitude":0.08209,"askPrice":2.12,"askSize":395,"bidPrice":2.1,"bidSize":900,"shortable":3,"etf":0,"ttmEps":-0.693447,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1758139200000},"marketStatusCode":2,"adr":0,"listingDate":1628222400000,"exchange":"NASDAQ","adjPreClose":2.01,"preHourTrading":{"tag":"盘前","latestPrice":2.01,"preClose":2.01,"latestTime":"09:19 EDT","volume":1778,"amount":3564.325485,"timestamp":1758115179276},"postHourTrading":{"tag":"盘后","latestPrice":2.06,"preClose":2.01,"latestTime":"19:58 EDT","volume":2609,"amount":5349.97,"timestamp":1758067092817},"volumeRatio":1.141379},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLYM\",,,,,undefined,":{"symbol":"CLYM","floatShares":25579273,"roa":"-15.83%","roe":"-22.92%","lyrEps":-1.5343,"volumeRatio":1.141379,"shares":67764100,"dividePrice":0,"high":2.185,"amplitude":0.08209,"preClose":2.01,"low":2.02,"week52Low":1.05,"pbRate":"0.77","week52High":8.6,"institutionHeld":0,"latestPrice":2.12,"committee":0.389961,"eps":-0.693447,"divideRate":0,"volume":407384,"delay":0,"ttmEps":-0.693447,"open":2.02,"prevYearClose":1.8,"prevWeekClose":2.25,"prevMonthClose":2.23,"prevQuarterClose":1.24,"fiveDayClose":2.38,"twentyDayClose":2.02,"sixtyDayClose":1.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CLYM\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-12","symbol":"CLYM","fiscalQuarterEnding":"2025/06","expectedEps":-0.19,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":-0.13},{"market":"US","date":"2021-09-13","symbol":"CLYM","fiscalQuarterEnding":"2021/06","expectedEps":-2.3,"name":null,"time":"","type":"earning","dateTimestamp":1631505600000,"reportTimeType":"","actualEps":-3.11}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CLYM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CLYM\",market:\"US\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":4,"updateTime":1755230400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CLYM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CLYM","date":"2025-09-16","current":-2.956473,"percent":0.26383,"low":-5.682799,"twenty":-3.160748,"median":-1.429631,"eighty":-1.050066,"high":-0.85032,"avg":-2.055014,"sd":1.274271,"marketCap":138238764},"quantilePoints":[{"date":"2024-10-04","current":-5.327624,"twenty":-5.327624,"median":-5.327624,"eighty":-5.327624,"marketCap":342006831},{"date":"2024-10-11","current":-5.369409,"twenty":-5.463426,"median":-5.390302,"eighty":-5.369409,"marketCap":344689237},{"date":"2024-10-18","current":-5.076912,"twenty":-5.494765,"median":-5.390302,"eighty":-5.327624,"marketCap":325912392},{"date":"2024-10-25","current":-4.85754,"twenty":-5.463426,"median":-5.327624,"eighty":-5.014234,"marketCap":311829757},{"date":"2024-10-31","current":-4.094958,"twenty":-5.404927,"median":-5.238831,"eighty":-4.776059,"marketCap":262875838},{"date":"2024-11-08","current":-3.677105,"twenty":-5.390302,"median":-5.014234,"eighty":-4.074065,"marketCap":236051773},{"date":"2024-11-15","current":-3.107258,"twenty":-5.373588,"median":-4.888879,"eighty":-3.806639,"marketCap":214779913},{"date":"2024-11-22","current":-2.917613,"twenty":-5.335981,"median":-4.293438,"eighty":-3.619939,"marketCap":201671280},{"date":"2024-11-29","current":-3.141297,"twenty":-5.327624,"median":-4.220314,"eighty":-3.127681,"marketCap":217132744},{"date":"2024-12-06","current":-2.830085,"twenty":-5.277482,"median":-3.974826,"eighty":-3.040153,"marketCap":195621141},{"date":"2024-12-13","current":-2.742557,"twenty":-5.237786,"median":-3.781569,"eighty":-2.995417,"marketCap":189571003},{"date":"2024-12-20","current":-1.896449,"twenty":-5.13959,"median":-3.671882,"eighty":-2.96235,"marketCap":131086332},{"date":"2024-12-27","current":-2.207661,"twenty":-5.051841,"median":-3.301766,"eighty":-2.921503,"marketCap":152597935},{"date":"2025-01-03","current":-2.013153,"twenty":-5.003788,"median":-3.151022,"eighty":-2.57139,"marketCap":139153183},{"date":"2025-01-10","current":-1.818646,"twenty":-4.962003,"median":-3.124277,"eighty":-2.236837,"marketCap":125708431},{"date":"2025-01-17","current":-1.954801,"twenty":-4.920218,"median":-3.063494,"eighty":-2.032604,"marketCap":135119757},{"date":"2025-01-24","current":-1.770019,"twenty":-4.870076,"median":-3.005142,"eighty":-1.952856,"marketCap":122347243},{"date":"2025-01-31","current":-1.876998,"twenty":-4.531614,"median":-2.995417,"eighty":-1.91979,"marketCap":129741856},{"date":"2025-02-07","current":-1.701941,"twenty":-4.324777,"median":-2.96624,"eighty":-1.892559,"marketCap":117641580},{"date":"2025-02-14","current":-1.546335,"twenty":-4.251653,"median":-2.932201,"eighty":-1.865328,"marketCap":106885778},{"date":"2025-02-21","current":-1.400454,"twenty":-4.228671,"median":-2.873849,"eighty":-1.840042,"marketCap":96802214},{"date":"2025-02-28","current":-1.351828,"twenty":-4.1451,"median":-2.528598,"eighty":-1.818646,"marketCap":93441026},{"date":"2025-03-07","current":-1.429631,"twenty":-4.03228,"median":-2.256288,"eighty":-1.756403,"marketCap":98818927},{"date":"2025-03-14","current":-1.293475,"twenty":-3.971692,"median":-2.18821,"eighty":-1.542445,"marketCap":89407600},{"date":"2025-03-21","current":-1.244848,"twenty":-3.871407,"median":-2.022879,"eighty":-1.474368,"marketCap":86046412},{"date":"2025-03-28","current":-1.159638,"twenty":-3.794104,"median":-1.954801,"eighty":-1.429631,"marketCap":85693751},{"date":"2025-04-04","current":-1.050066,"twenty":-3.724618,"median":-1.940213,"eighty":-1.381004,"marketCap":77596704},{"date":"2025-04-11","current":-1.059197,"twenty":-3.680923,"median":-1.925625,"eighty":-1.357663,"marketCap":78271458},{"date":"2025-04-17","current":-1.150507,"twenty":-3.672927,"median":-1.896449,"eighty":-1.324596,"marketCap":85018997},{"date":"2025-04-25","current":-1.187031,"twenty":-3.573219,"median":-1.876998,"eighty":-1.28764,"marketCap":87718013},{"date":"2025-05-02","current":-1.150507,"twenty":-3.328025,"median":-1.867273,"eighty":-1.252628,"marketCap":85018997},{"date":"2025-05-09","current":-1.088206,"twenty":-3.166583,"median":-1.847822,"eighty":-1.218825,"marketCap":80415162},{"date":"2025-05-16","current":-0.872124,"twenty":-3.152968,"median":-1.818646,"eighty":-1.187031,"marketCap":81090920},{"date":"2025-05-23","current":-0.872124,"twenty":-3.141297,"median":-1.818646,"eighty":-1.164325,"marketCap":81090920},{"date":"2025-05-30","current":-0.886659,"twenty":-3.134489,"median":-1.784607,"eighty":-1.159638,"marketCap":82442435},{"date":"2025-06-06","current":-0.901194,"twenty":-3.10434,"median":-1.750568,"eighty":-1.150507,"marketCap":83793951},{"date":"2025-06-13","current":-0.930265,"twenty":-3.086835,"median":-1.590099,"eighty":-1.125277,"marketCap":86496981},{"date":"2025-06-20","current":-0.893927,"twenty":-3.063494,"median":-1.522022,"eighty":-1.106495,"marketCap":83118193},{"date":"2025-06-27","current":-0.91573,"twenty":-3.014867,"median":-1.478258,"eighty":-1.095721,"marketCap":85145466},{"date":"2025-07-03","current":-0.930265,"twenty":-3.007087,"median":-1.439356,"eighty":-1.066502,"marketCap":86496981},{"date":"2025-07-11","current":-0.981139,"twenty":-2.997362,"median":-1.429631,"eighty":-1.007303,"marketCap":91227285},{"date":"2025-07-18","current":-1.061084,"twenty":-2.995417,"median":-1.400454,"eighty":-0.995674,"marketCap":98660619},{"date":"2025-07-25","current":-1.075619,"twenty":-2.995417,"median":-1.376141,"eighty":-1.007303,"marketCap":100012135},{"date":"2025-08-01","current":-1.017477,"twenty":-2.979856,"median":-1.361553,"eighty":-1.016024,"marketCap":94606073},{"date":"2025-08-08","current":-1.220973,"twenty":-2.968185,"median":-1.346965,"eighty":-1.017477,"marketCap":113527288},{"date":"2025-08-15","current":-2.492713,"twenty":-2.95846,"median":-1.351828,"eighty":-1.023291,"marketCap":116554252},{"date":"2025-08-22","current":-3.173861,"twenty":-2.979856,"median":-1.366416,"eighty":-1.024745,"marketCap":148403379},{"date":"2025-08-29","current":-3.333278,"twenty":-3.007087,"median":-1.381004,"eighty":-1.030392,"marketCap":155857430},{"date":"2025-09-05","current":-3.376756,"twenty":-3.075164,"median":-1.400454,"eighty":-1.031929,"marketCap":157890353},{"date":"2025-09-12","current":-3.478204,"twenty":-3.149077,"median":-1.429631,"eighty":-1.042845,"marketCap":162633840},{"date":"2025-09-16","current":-2.956473,"twenty":-3.160748,"median":-1.429631,"eighty":-1.050066,"marketCap":138238764}],"updateTime":1758099542920},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CLYM\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2537220152","title":"Climb Bio Inc. Announces Leadership Changes: Brett Kaplan Departs, Aoife Brennan Appointed Interim Principal Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2537220152","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537220152?lang=en_us&edition=fundamental","pubTime":"2025-05-24 04:45","pubTimestamp":1748033120,"startTime":"0","endTime":"0","summary":"Climb Bio Inc. Announces Leadership Changes: Brett Kaplan Departs, Aoife Brennan Appointed Interim Principal Financial Officer. Climb Bio Inc. announced a change in its management team with the departure of Chief Operating Officer Brett Kaplan, M.D., effective May 23, 2025. Following this, Aoife Brennan has been appointed as the interim principal financial officer, effective May 24, 2025. Dr. Brennan has been serving as the President and Chief Executive Officer of Climb Bio since June 2024.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nNDLbCgV58:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","CLYM"],"gpt_icon":0},{"id":"2536363031","title":"Climb Bio Inc. Announces Inducement Equity Award Grant for New Employee Under 2025 Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2536363031","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536363031?lang=en_us&edition=fundamental","pubTime":"2025-05-20 04:35","pubTimestamp":1747686900,"startTime":"0","endTime":"0","summary":"Climb Bio Inc., a biotechnology company focused on developing therapeutics for immune-mediated diseases, announced on May 19, 2025, the granting of an inducement equity award to a new employee under its 2025 Inducement Plan. This award, in line with Nasdaq Listing Rule 5635, comprises a non-statutory stock option to purchase up to 120,000 shares of the company's common stock at an exercise price of $1.27 per share, matching the closing price on the grant date. The option, which has a ten-year term, vests over four years, with 25% becoming exercisable on the first anniversary of the employee's start date and the rest vesting in 36 equal monthly installments, contingent on ongoing employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nNDLb8jK2X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2210150020.SGD","IE00B64PRP62.GBP","BK4585","BK4539","BK4588","CLYM","IE00BGHQF748.EUR","LU2095319765.USD","IE00BKPKM429.USD","BK4112","NDAQ","IE00B3QW5Z07.USD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2535025265","title":"BRIEF-Climb Bio Reports First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2535025265","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535025265?lang=en_us&edition=fundamental","pubTime":"2025-05-14 20:03","pubTimestamp":1747224180,"startTime":"0","endTime":"0","summary":"BRIEF-Climb Bio Reports First Quarter 2025 Financial Results May 14 (Reuters) - Climb Bio Inc CLYM.O:CLIMB BIO REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATESCLIMB BIO INC -","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nTUAXVTQF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","BK4139","BK4539"],"gpt_icon":0},{"id":"2535127047","title":"Climb Bio Q1 EPS $(0.31) Misses $(0.15) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2535127047","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535127047?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:12","pubTimestamp":1747221132,"startTime":"0","endTime":"0","summary":"Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.15) by 106.67 percent. This is a 416.67 percent decrease over losses of $(0.06) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45402677/climb-bio-q1-eps-0-31-misses-0-15-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM"],"gpt_icon":0},{"id":"2535981042","title":"Climb Bio Inc. Reports Q1 2025 Financial Results with Increased R&D Expenses Amid Strong Cash Position; No Specific Sales or Net Income Data Provided","url":"https://stock-news.laohu8.com/highlight/detail?id=2535981042","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535981042?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:00","pubTimestamp":1747220451,"startTime":"0","endTime":"0","summary":"Climb Bio Inc. Reports Q1 2025 Financial Results with Increased R&D Expenses Amid Strong Cash Position; No Specific Sales or Net Income Data Provided. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on May 14, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL7Y1rQX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","NDAQ"],"gpt_icon":0},{"id":"2535042243","title":"Press Release: Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2535042243","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535042243?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:00","pubTimestamp":1747220400,"startTime":"0","endTime":"0","summary":"Clinical Trials of Budoprutug in Primary Membranous Nephropathy , Immune Thrombocytopenia , and Systemic Lupus Erythematosus  on Track to Initiate in 2025. CLYM116 Progressing Towards Anticipated IND or CTA Submission in Second Half 2025. Appointed Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors and Perrin Wilson, Ph.D., as Chief Business Officer. Strong Financial Position, with Cash Runway Expected Through 2027. \"2025 is a critical year of execution for Climb Bio and we continue to make excellent progress developing a differentiated pipeline targeting immune-mediated diseases with expansive therapeutic and commercial potential,\" said Aoife Brennan, President and CEO of Climb Bio. \"Our most advanced program, budoprutug, a potential best-in-class anti-CD19 monoclonal antibody designed to treat B-cell mediated diseases, remains on track to initiate clinical studies in ITP and SLE in the coming weeks and in pMN in the second half of 2025. We plan to provide clarity on the","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP","CLYM","BK4077","SLE","BK4539","BK4199","CTA","BK4139"],"gpt_icon":0},{"id":"2524191799","title":"Press Release: Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2524191799","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524191799?lang=en_us&edition=fundamental","pubTime":"2025-04-01 19:00","pubTimestamp":1743505200,"startTime":"0","endTime":"0","summary":"Appointments Include Industry Veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors. WELLESLEY HILLS, Mass., April 01, 2025  -- Climb Bio, Inc.  today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair.Bo Cumbo brings over 30 years of experience in the pharmaceutical and biotechnology industries, with a proven track record of leading successful commercial launches for 11 specialty and rare disease therapies. He currently serves as President, Chief Executive Officer, and director of Solid Biosciences . Previously, Mr. Cumbo was President and Chief Executive Officer of AavantiBio, Inc. Before that, he held key leadership roles at Sarepta Therapeutics, Inc., where he most recently served as Executive Vice President and Chief Commercial Officer. Earlier in his career, he held","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NQmain","CLYM","BK4139"],"gpt_icon":0},{"id":"2522382688","title":"BRIEF-Climb Bio Files For Offering Of Common Stock Up To $22.4 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522382688","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522382688?lang=en_us&edition=fundamental","pubTime":"2025-03-26 04:40","pubTimestamp":1742935215,"startTime":"0","endTime":"0","summary":"BRIEF-Climb Bio Files For Offering Of Common Stock Up To $22.4 Million - SEC FilingMarch 25  - Climb Bio Inc CLYM.O:CLIMB BIO INC: FILES FOR OFFERING OF COMMON STOCK UP TO $22.4 MILLION - SEC FILINGSource text: [ID:n0001193125-25-062602]Further company coverage: CLYM.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q81D3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLYM"],"gpt_icon":0},{"id":"2522634880","title":"Climb Bio Reports Fourth Quarter And Year-End 2024 Financial Results And Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2522634880","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522634880?lang=en_us&edition=fundamental","pubTime":"2025-03-26 04:20","pubTimestamp":1742934019,"startTime":"0","endTime":"0","summary":"March 25 (Reuters) - Climb Bio Inc ::*CLIMB BIO REPORTS FOURTH QUARTER AND YEAR-END 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES*CLIMB BIO INC - EXPECTS CASH RUNWAY THROUGH 2027*CLIMB BIO INC:","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nRSDrXHnL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","BK4139"],"gpt_icon":0},{"id":"2522288770","title":"Climb Bio Q4 2024 GAAP EPS $(0.13) Beats $(0.15) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2522288770","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522288770?lang=en_us&edition=fundamental","pubTime":"2025-03-26 04:08","pubTimestamp":1742933328,"startTime":"0","endTime":"0","summary":"Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.15) by 13.33 percent. This is unchanged from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44481370/climb-bio-q4-2024-gaap-eps-0-13-beats-0-15-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM"],"gpt_icon":0},{"id":"2522887962","title":"Press Release: Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2522887962","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522887962?lang=en_us&edition=fundamental","pubTime":"2025-03-26 04:05","pubTimestamp":1742933100,"startTime":"0","endTime":"0","summary":"Received Clearance from the U.S. Food and Drug Administration  for Clinical Trials of Budoprutug in Primary Membranous Nephropathy , Immune Thrombocytopenia , and Systemic Lupus Erythematosus . Completed Studies to Support Process Optimization through Cell Line Switch for Budoprutug and Filed Additional Patent Applications to Further Strengthen Intellectual Property Position. Expanded Pipeline to Include CLYM116, an Anti-APRIL  Monoclonal Antibody for Treatment of IgA Nephropathy . Appointed Perrin Wilson, Ph.D. as Chief Business Officer. Ended 2024 in a Strong Financial Position, with Cash Runway Expected Through 2027. received clearance from the FDA to initiate a Phase 2 clinical trial of. budoprutug in patients with pMN. This open-label, dose-ranging","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","BK4139","BK4077","BK4199","SLE","ITP"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":35,"code":"91000000","status":"200"}]}}